PHARMACY

NACDS names Kathleen Jaeger SVP pharmacy care, patient advocacy

BY Antoinette Alexander

ALEXANDRIA, Va.  — The National Association of Chain Drug Stores has appointed pharmacist and trade association veteran Kathleen Jaeger to fill the newly enhanced position of SVP pharmacy care and patient advocacy. She also will serve in a separate role as president of the NACDS Foundation.

Jaeger will assume her new positions on Nov. 28, and will report to NACDS president and CEO Steve Anderson.

“With 24 years of experience and leadership as a trade association CEO, pharmacist, attorney and advocate, Kathleen Jaeger will serve as a clear and compelling voice for the value of community pharmacy and for the needs of patients in this new and expanded role at NACDS,” Anderson stated.

“NACDS’ absolute commitment to telling the story of community pharmacies as the face of neighborhood health care has brought us to the point that pharmacy no longer is talking only to itself," Anderson continued. "We are raising awareness of the value of pharmacy among consumers and patients, among elected officials and policymakers, among the media and among all healthcare partners and stakeholders. Now, it is time to take this work to the next level of success.”

Previously, Jaeger has served as EVP and CEO of the National Community Pharmacists Association and as president and CEO of the Generic Pharmaceutical Association. She also has been a partner in the food and drug practices of national law firms Kirkpatrick & Lockhart and McKenna & Cuneo. She also has served as a hospital pharmacist at the National Institute of Health.

As NACDS’ SVP pharmacy care and patient advocacy, Jaeger will serve as a spokeswoman for pharmacy patient care before key constituencies and target audiences, including in the media and at public and healthcare events. She also will direct the staff of the newly renamed Pharmacy Care and Patient Advocacy Department, which advances pharmacy information and research, conducts outreach with NACDS members and with external constituencies, including colleges and schools of pharmacy, and provides pharmacy insights and expertise that contribute to NACDS’ public policy advocacy and communications initiatives.

“Every day, countless patient care success stories play out in pharmacies in neighborhoods across America. I look forward to helping to tell this story to advance patient care, and I look forward to doing so with the insights and true passion that flow from being a pharmacist and the daughter of a pharmacist," Jaeger stated. "It is a distinct honor to represent community pharmacy and the value that it delivers to patients and to the broader healthcare system."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA approves Eylea

BY Allison Cerra

SILVER SPRING, Md. — After being unanimously recommended for approval by a Food and Drug Administration panel, the FDA has approved an eye disorder treatment created by Regeneron Pharmaceuticals.

The FDA on Friday approved Eylea (aflibercept) to treat patients with wet age-related macular degeneration, a leading cause of vision loss and blindness. The wet form of AMD includes the growth of abnormal blood vessels, which can leak fluid into the central part of the retina, also known as the macula. When fluid leaks into the macula, the macula thickens and vision loss occurs. An early symptom of wet AMD occurs when straight lines appear to be wavy, the FDA noted.

The drug was recommended for approval back in June by the Dermatologic and Ophthalmic Drugs Advisory Committee.

"Eylea is an important new treatment option for adults with wet AMD," said Edward Cox, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. "It is a potentially blinding disease and the availability of new treatment options is important."


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

CVS/pharmacy kicks off annual campaign to support St. Jude Children’s Research Hospital

BY Antoinette Alexander

WOONSOCKET, R.I. — CVS/pharmacy once again is supporting the St. Jude Children’s Research Hospital Thanks and Giving campaign, and will offer CVS/pharmacy shoppers more options to support the research.

This year marks the eighth year for the annual in-store fundraiser. St. Jude is one of the world’s leading centers for the research and treatment of pediatric cancer and other deadly childhood diseases, and since partnering in 2004, CVS/pharmacy and its customers have raised more than $25 million for the hospital.

From now through Dec. 11, CVS/pharmacy store colleagues will encourage customers to add $1 or $3 to their purchase at the register. Customers shopping online at CVS.com also can support the campaign by donating the amount of their choice at checkout.

Funds raised by CVS/pharmacy for Thanks and Giving will support the CVS Caremark Rehabilitation Services Center at St. Jude. Children with deadly diseases, such as cancer, may experience developmental, cognitive or physical impairments as a result of their illnesses, as well as the treatments used to save their lives. The facility in Memphis, Tenn., which opened in 2009, doubled the space dedicated to providing audiology, occupational therapy, physical therapy and speech-language pathology services to St. Jude patients to help them overcome the barriers they face in recovery.

"CVS/pharmacy’s participation in the Thanks and Giving campaign reflects our commitment and dedication to supporting the work St. Jude is doing to treat children with cancer and the life-saving research they share with experts across the country," said Eileen Howard Boone, SVP corporate communications and community relations for CVS Caremark. "We want to thank our colleagues and customers who, for the past eight years, have joined us in supporting this great cause."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES